Antioxidants, Vol. 11, Pages 2316: Effects of Antioxidant Gene Overexpression on Stress Resistance and Malignization In Vitro and In Vivo: A Review

ALDH3A1in vitroIncreased resistance: 4-hydroxyperoxycyclophosphamide, doxorubicin, etoposide, 5-FU, γ-ray, H2O2 [72]CATin vitroIncreased resistance: UVB [73], benzo(a)pyrene [74], paraquat [81], H2O2 [83,89,90,91], benzyl isothiocyanate [84], dexamethasone [86], temozolomide, γ-ray, staurosporine [88], combination of ascorbate and menadione [90]
Unchanged resistance: γ-ray [82], paraquat, TBHP [83], TNF-alpha [85], γ-ray, 5-FU, cisplatin, doxorubicin [90]
Decreased resistance: Cr (VI) [87], paclitaxel, etoposide, arsenic trioxide, aminotriazol [90]in vivoIncreased resistance: benzo(a)pyrene [75,76], H2O2 [77], doxorubicin [78], proton radiation [79,80]
Unchanged resistance: γ-ray [82]SOD1 +
CATin vivoIncreased resistance: benzo(a)pyren [75]GCLCin vitroIncreased resistance: γ-ray [93], UVC [94], tamoxifen [95]in vivoIncreased resistance: paraquat [92]GCLC+
GCLMin vitroIncreased resistance: γ-ray [93]GCLMin vitroIncreased resistance: γ-ray [93]GPX1in vitroIncreased resistance: UVB [96], deoxynivalenol [97], cisplatin [99,103,105], X-ray [100], doxorubicin [106], H2O2, GSH high concentration [107]
Decreased resistance: cisplatin [103], gemcitabine [104]in vivoIncreased resistance: ischemia-reperfusion injury [98], cocaine [101], microcystin-leucine-arginine [102]GPX2in vitroIncreased resistance: cisplatin [108]GPX3in vitroIncreased resistance: ascorbate [109], cisplatin [110], NAPQI [111]GPX4in vitroIncreased resistance: hypericin + PDT [112], TBHP [113], H2O2, erastin [114], AAPH, 5-HPETE [115], staurosporine, etoposide, UVB, actinomycin D, cycloheximide [116]
Unchanged resistance: etoposide [113], calcium ionophore A23187 [116]GSRin vitroIncreased resistance: temozolomide, cisplatin [117], H2O2 [118]GSTP1in vitroIncreased resistance: hypericin+PDT [112]mt-PRDX5in vitroIncreased resistance: H2O2 [119] mt-SOD1in vitroIncreased resistance: γ-ray [51]mt-CATin vitroIncreased resistance: γ-ray [82]mt-CAT + SOD2in vitroIncreased resistance: γ-ray [82]MTIin vitroIncreased resistance: TBHP, CdCl2 [120], Zn(II) [121]
Unchanged resistance: alkylating agents [121]MTIIin vitroIncreased resistance: MNU, MNNG [122], cisplatin, melphalan, chlorambucil [123], streptozotocin [124]
Unchanged resistance: bleomycin [122,123], γ-ray, MMS, N-hydroxyethyl N-chloroethylnitrosourea [122], 5-FU, vincristine, doxorubicin [123]NFE2L2in vitroIncreased resistance: UVA+UVB [125], cisplatin [126,128,129,130], 5-FU [126,130], γ-ray [126], TBHP [127], X-ray [73], tamoxifen [131], gemcitabine [132]NQO1in vitroIncreased resistance: tamoxifen [95]nuclear-PRDX5in vitroUnchanged resistance: H2O2 [119]PON1in vitroIncreased resistance: 5-fluorouracil, paclitaxel, cisplatin, etoposide [133], streptozotocin (mouse model of diabetes) [138] in vivoIncreased resistance: arthritis induction (K/BxN serum transfer (STIA) or collagen antibody transfer (CAIA) to mice [134], carbon tetrachloride [135,137], elastase-induced abdominal aortic aneurysm [136]PON2in vitroIncreased resistance: y-ray [139], tert-butyl-hydroperoxide [140], cisplatin [141], dexamethasone [142], oxygen-glucose deprivation/reoxygenation exposure [143], Nε-(carboxymethyl) lysine [144], pyocyanin [145], hypoxia [146], 2,3-dimethoxy-1,4-naphthoquinone [148]
Unchanged resistance: dacarbazine [141]in vivoIncreased resistance: dexamethasone [142], apolipoprotein E deficiency [147]PON3in vivoIncreased resistance: carbon tetrachloride [135,149]PRDX1in vitroIncreased resistance: thiosemicarbazone iron chelator triapine [150], glucose oxidase [151], BCNU [62], γ-ray [65,152], 6-hydroxydopamine [152], doxorubicin [154]PRDX2in vitroIncreased resistance: H2O2 [58,155], γ-ray [156], 6-hydroxydopamine [153], doxorubicin [154]in vivoIncreased resistance: 6-hydroxydopamine [153], ischemia [176]PRDX3in vitroIncreased resistance: H2O2 [157], doxorubicin [154], arsenic trioxide [158]
Unchanged resistance: 6-hydroxydopamine [153]PRDX4in vitroIncreased resistance: γ-ray [66], urethane [159], photon radiation [160], 6-hydroxydopamine [153]
Unchanged resistance: doxorubicin [154]PRDX5in vitroIncreased resistance: H2O2 [161,162,165], TBHP [162], MPP+ [163], adriamycin, etoposide [164], menadione, cigarette smoke extract [165], shikonin [166], emodin [167], β-Lapachone [168], doxorubicin [154]PRDX6in vitroIncreased resistance: cisplatin [169], doxorubicin [170], hypoxia, cobalt chloride [171], UVA, menadione [172], H2O2 [173], X-ray [175]
Decreased resistance: TNF-α/CHX solution [173]in vivoIncreased resistance: UVA, UVB [172], urethane [174]SLC31A1in vitroIncreased resistance: paraquat [177]SLC7A11in vitroIncreased resistance: cisplatin [178], temozolomide [179]SOD1in vitroIncreased resistance: γ-ray [181,183], S-nitroso-N-acetylpenicillamine, spermine-NONOate, diethylamine-NONOate [182], paraquat [83,177], cisplatin [186,187], docosahexaenoic acid [188], xanthine oxidase, hypoxanthine, menadione [189], TBHP [83], benzyl isothiocyanate [84], TNF and hyperthermia [190], Bortezomib [191], phenazine methosulfate [192]
Unchanged resistance: γ-ray [51,180,193], N-methyl-D-aspartate, kainic acid, glutamate [182], H2O2 [83,182], UVB [73]
Decreased resistance: menadione [182], Cr (VI) [87]in vivoIncreased resistance: paraquat, γ-ray [184], benzo(a)pyrene [75,76]
Unchanged resistance: hyperoxia, paraquat [185]SOD1 + CATin vitroIncreased resistance: paraquat, H2O2 [83], UVB [73]
Unchanged resistance: TBHP [83]SOD2in vitroIncreased resistance: paraquat [180], γ-ray [51,82,181,195,196,203,205,206], cisplatin [194,201], X-ray [197], doxorubicin [198,200], docetaxel [200], 2-methoxyestradiol [202], glutamate [56], TNF- alpha [85], H2O2 [204], menadione, epirubicin [207]
Unchanged resistance: γ-ray [193,206]
Decreased resistance: Cr (VI) [87]in vivoIncreased resistance: γ-ray [51,82]
Unchanged resistance: 100% O2 [199]mt-signal deleted SOD2in vitroUnchanged resistance: γ-ray [51]SOD2 + CATin vitroUnchanged resistance: TNF-alpha [85] SOD3in vitroIncreased resistance: H2O2 [211]in vivoIncreased resistance: 4-MV photon radiation [208], ischemia [209], 12-O-tetradecanoylphorbol-13-acetate [210], lipopolysaccharide induced endotoxemia [20]TXNin vitroIncreased resistance: H2O2 [212,220,224], daunomycin [213], MPP+ [215], menadione, 1-chloro-2,4-dinitrobenzene [71], arsenic trioxide [222,223]
Unchanged resistance: dexamethasone, doxorubicin, etoposide [220], auranofin, juglone [71]in vivoIncreased resistance: methamphetamine [214,221], sepsis-induced myocardial dysfunction, sham surgery [216], ischemia [217,225], ex vivo ischemia [218], adriamycin [219]TXNL1in vitroDecreased resistance: cisplatin [226]TXNRD1in vitroIncreased resistance: X-ray [227], H2O2 [224]

留言 (0)

沒有登入
gif